Torigen CEO wins 2019 Entrepreneur of the Year Award

Emergence client Torigen Pharmaceuticals Inc., a startup in companion animal immuno-oncology, announces its founder and chief executive officer, Ashley Kalinauskas, has been honored as the 2019 Entrepreneur of the Year in the Scalable Venture category (under $1 million in sales) by the CT Entrepreneur Awards. Kalinauskas was recognized for her entrepreneurial achievements in 2018 with the company’s first product, an autologous prescription product for dogs and cats that uses the animal’s own tumor cells to create a personalized immunotherapy.

In 2018, Torigen hit several major milestones, including completion of its Series A with a $2.3 million equity raise, and treated nearly 250 companion animals diagnosed with cancer last year. Torigen also was named the 2018 Top Animal Health Innovation at the Kansas City Animal Health Investment Forum and a Million Dollar Women Company. Torigen was nominated for the CT Entrepreneur Awards by the UCONN Technology Incubation Program (TIP), recognized as having high potential for organizational growth.

“I’m extremely proud and humbled to be a part of a remarkable team at Torigen,” said Kalinauskas. “To be considered among this distinguished group of entrepreneurs and companies is a testament to the passion we each feel in our pursuit of life-changing solutions for pets with cancer. Thank you to UCONN TIP and the CT Entrepreneur Event Organizers Consortium for making this award possible.”

The annual CT Entrepreneur Awards identify, recognize and celebrate Connecticut’s leading entrepreneurs, ventures and ecosystem elements that support them. Nominations for the 2019 CT Entrepreneur Awards began in December 2018, and finalists were selected for a 30-day community-voting period from February to March 2019. The winners were announced April 18, 2019.

Cancer is the number-one cause of death in dogs over the age of two, and one in four dogs will be impacted by cancer in their lifetimes. Torigen is offering exciting potential for pets with cancer through its Autologous Prescription Product, which works by stimulating an immune response that targets and destroys the cancer cells specific to the patient.

Experimental autologous cancer vaccines created by Torigen Pharmaceuticals Inc. are regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.

For more information, email, visit or call 860-519-9956.

About Torigen Pharmaceuticals Inc.
Torigen Pharmaceuticals Inc. is focused on delivering affordable companion animal immuno-oncology products. Its initial patented product line utilizes a portion of the pet-patient’s tumor to create a personalized cancer vaccine. With over 10 years of supporting pre-clinical publications, the Torigen team is focused on developing innovative veterinary cancer biologics that allow for the body to recognize foreign tumor–associated antigens and facilitate the reversal of immune senescence. For more information, please visit

(Source: FARMINGTON, Conn., May 7, 2019 /PRNewswire-PRWeb)

Note: Ashley Kalinauskas, Torigen Pharmaceuticals CEO, will present at VetHealth Global 2019, June 24-26th in Charlottetown, Prince Edward Island.

Posted in Clients

What Emergence Clients are Hiring?

Here is a summary of the Emergence clients advertising job opportunities this week:

Posted in Careers

Chinova Bioworks will participate in Sephora’s Accelerator in May

Chinova Bioworks was selected to join 2019 Sephora Accelerate which builds a community of innovative female founders in beauty. Sephora’s site offers some background on the program:

Even in the beauty industry, where most customers are women, female founders are still underrepresented. We saw a unique opportunity to draw from our history of working with beauty entrepreneurs to build a supportive community for women who are in the early stages of developing their businesses. Accelerate is a key initiative of a larger program called Sephora Stands, which aims to use Sephora’s strengths for even greater good in our communities. We hope to build an ecosystem of support for more than 50 women-led beauty businesses by 2020.

Founders will participate in a week-long Bootcamp in San Francisco, May 5-11, and have a follow-up opportunity to pitch to Sephora’s Merchandising and Innovation teams on Demo Day this Fall.

Chinova Bioworks has developed a natural preservative, Chiber Mushroom Extract, to extend shelf life in foods, beverages, cosmetics and personal care items.

Posted in Clients

Because Animals sees opportunities for Lab Grown Meat

New Emergence client, Because Animals, started by two Torontonians, is a company making human grade sustainable, animal-free pet food. Shannon Falconer has a PhD in microbial chemical biology and worked as a postdoctoral fellow at Stanford University. Joshua has worked as a journalist, banker and cat rescuer. He graduated with an MBA from Indiana University’s Kelley School of Business. Because Animals already has a couple of superfood supplements for both dogs and cats, and now they are developing lab-grown meat for pet food. They recently announced a prototype cat treat. They are one of the companies that sees opportunities.  Read more here.

Posted in Clients

Center for Aquaculture Technologies (CAT) announces sale to Cuna del Mar

On April 23, 2019, all shares in leading aquaculture R&D company The Center for Aquaculture Technologies (CAT), were purchased by Cuna Del Mar LP (CDM), a US-based aquaculture investment fund, for an undisclosed amount from Linnaeus Capital Partners BV.

Dr. John Buchanan, CEO of CAT, commented: “We look forward to working within Cuna del Mar, a fund that clearly sees the potential for growth in the aquaculture industry.”

Robert Orr, Managing Director of Cuna Del Mar, added “Cuna del Mar is very pleased to be acquiring the CAT operations in the USA and Canada. CAT has a tremendously talented team of people with unique capabilities, who are dedicated to making a difference for our customers and the industry as a whole. We are excited about the possibilities the future holds for this business.”

CAT currently operates two laboratories: its research hub in San Diego, California, and state-of-the-art wet lab facilities including BSL 3 containment for aquatic animal pathogens, located on Prince Edward Island in Canada. Thanks to the expertise of its team and the unique versatility of its laboratories, CAT is enabling the aquaculture industry to achieve efficient production of through genetic improvement as well as facilitating commercial development of innovative feed and health management products and services.

With Cuna Del Mar, CAT looks forward to working with other companies within the CDM portfolio and to expanding its capacity for conduct of aquaculture contract research and services in support of the global aquaculture industry.

For more information, please contact Debbie Plouffe at or at 902-687-1245.

CAT is a member of the Emergence Bio-incubator.

Posted in Clients

RPS Biologiques Announces Health Canada Approval of SupratectTM; the First Veterinary Health Product Approved for use in Finfish Aquaculture

RPS Biologiques Inc. is pleased to announce the reception of two (2) Notification Numbers from the Health Canada Veterinary Drugs Directorate (VDD) for their Veterinary Health Products (VHP), Supratect-L and Supratect -P. The Notification Numbers indicate approval, allowing for marketing and sale of Supratect in Canada. The use of Supratect has been fully tested for the maintenance of optimal health of fish and fish eggs in finfish species. It consists of natural ingredients that are completely safe and beneficial for the target species. Supratect is the first and only current Natural fish health product to receive approval, in Canada, through the Veterinary Health Products notification program.

The President of RPS Biologiques, Dr. Subrata Chowdhury, says the objective of the company is to become a leader in developing safe, all natural, fish health products for use in the aquaculture sector. Dr. Chowdhury is a molecular biologist with wide experience in the fields of microbiology, virology, immunology and genetics. He notes that RPS Biologiques is continuing to develop additional, unique natural products for use in the animal health sector.

The testing undertaken to validate Supratect was completed, over a three-year period, mainly at the Huntsman Marine Science Centre located in St Andrews, New Brunswick. Established in 1969, Huntsman is a private, not-for-profit research and science based teaching institution whose work is recognized throughout Canada and internationally.

Paul Dick & Associates (PDA), a global consulting company, worked with RPS Biologiques and Health Canada to obtain notification for Supratect via the VHP program. The firm specializes in the development and registration of animal and human health products including veterinary biologics, veterinary drugs, feeds and natural health products.

RPS Biologiques Inc is a privately-owned Canadian company based in Charlottetown, Prince Edward Island and a member of the PEI Bioalliance Emergence Bio-incubator.

Posted in Clients

Dosecann hiring for 12 new positions

Emergence client Dosecann, a PEI-based Licensed Dealer developing a suite of cannabis products across a variety of delivery methods for both the medical and adult use markets, is currently hiring for 12 new positions. Positions include:

  • HR Manager
  • Analytical Scientist I
  • Warehouse Clerk
  • HR Manager
  • Analytical Scientist II
  • Analytical Scientist III
  • QC Chemist
  • Extraction Technician
  • Formulation Scientist
  • Packaging Technician
  • QA Specialist
  • QA Support – Validation/Documentation

See more details on these positions here.

Dosecann has assembled a world-class team housed in a purpose-built, 42,000 sqft. GMP compliant facility that will be the hub for cannabis extraction, product innovation and formulation.

Posted in Clients

Ethicann Pharmaceutical Closes Successful Financing Round

Emergence client Ethicann Pharmaceuticals, a company that sources pharmaceutical-grade botanically sourced cannaboid oils to formulate ethical drugs has closed a successful initial financing round. Several Canadian and US venture funds and high net worth individuals and entrepreneurs with considerable industry experience are the investors.

One of Ethicann’s recent milestones saw their US subsidiary holding successful Pre-IND meeting with the US Food and Drug Administration to discuss the 505(b)2 requirements for a marketing approval for its first product (CAN-001) to treat chemotherapy-induced nausea and vomiting.

For more details on the company and their latest achievement, click here..

Posted in Clients

Avivagen pursuing opportunities for combining OxC-beta with Cannabis products

Avivagen has been analyzing opportunities to combine their propietary product OxC-betaTM with licensed cannabis products and they believe there are various combinations that could result in new products for the company. For the full news release, click here.

“We are enthusiastic about working with leading edge cannabis companies and participating in their development of a line of products which incorporate our unique OxC-beta™ technology,” says Kym Anthony, Chairman and Interim CEO, Avivagen. “We have been vocal advocates for the benefits of new product categories and look forward to collaborating with these large, well-resourced and innovative companies to bring these innovative products to the worldwide market, where appropriate.”

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit

Posted in Clients

SomaDetect Chosen for Global Business Accelerator

Emergence client SomaDetect will join other innovators to be part of the 2019 Pearse Lyons Accelerator. In its third year, this Accelerator received 250 applications worldwide and SomaDetect was among only 10 startups chosen. Together they offer a glimpse of what the future of farming will be. See the full list here. These startups will gain access to expertise, funding, networking, presentation and mentorship opportunities that will boost their global success.

This good news adds to their growing list of achievements that include receiving $1M US as the top startup in the Buffalo-based 43North accelerator’s 2017 cohort and, in 2018, investment from the Dairy Farmers of America which represents almost 15,000 farmers. For a full list of achievement, read their news here.

Read more about the Pearse Lyons Accelerator here.

Posted in Clients